Company Description
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib.
Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
| Country | United States |
| Founded | 2011 |
| IPO Date | Sep 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 155 |
| CEO | Brian Sullivan |
Contact Details
Address: 2800 Campus Drive, Suite 140 Minneapolis, Minnesota 55441 United States | |
| Phone | (763) 392-0123 |
| Website | celcuity.com |
Stock Details
| Ticker Symbol | CELC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001603454 |
| CUSIP Number | 15103L101 |
| ISIN Number | US15102K1007 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Brian F. Sullivan | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Lance G. Laing Ph.D. | Co-Founder, Chief Science Officer, Vice President, Secretary and Director |
| Vicky Hahne CPA | Chief Financial Officer |
| Jodi Sievers | Head of Investor Relations and Corporate Communications |
| Brent Eilefson | General Counsel |
| Sheri Smith | Acting Head of Clinical Operations |
| Igor Gorbatchevsky M.D. | Chief Medical Officer |
| Eldon C. Mayer III, M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 8, 2026 | 8-K | Current Report |
| Jun 5, 2026 | 424B5 | Filing |
| Jun 5, 2026 | 305B2 | Filing |
| Jun 4, 2026 | FWP | Free Writing Prospectus |
| Jun 3, 2026 | 424B5 | Filing |
| Jun 2, 2026 | 8-K | Current Report |
| May 20, 2026 | 8-K/A | [Amend] Current report |
| May 18, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 18, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G | Filing |